An in vivo test to assess mefloquine 25 mg/kg for the treatment of uncomplicated falciparum malaria in Rondônia, Brazil
Braz. j. infect. dis
;
10(4): 279-282, Aug. 2006. mapas, tab
Article
in English
| LILACS
| ID: lil-440683
ABSTRACT
Drug-resistant Plasmodium falciparum is undermining malaria control efforts worldwide. In Brazil, mefloquine (MQ) at a dose of 15 mg/kg body weight is used to treat P. falciparum. At this dose, MQ resistance developed rapidly in Thailand. Use of a higher MQ dose may retard the development of resistance. We treated 50 patients aged one to 67 years who had acute, uncomplicated P falciparum malaria using MQ 25 mg/kg. There were no serious adverse events. Two patients complained of dizziness and insomnia. Assessing evaluable patients, the day 42 cure rate was 40/42 [95.2 percent (95 percent confidence interval 83.8 to 99.4 percent)]. Mefloquine was efficacious and well tolerated in this small cohort from the state of Rôndonia.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Mefloquine
/
Malaria, Falciparum
/
Antimalarials
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2006
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Tropical Medicine Research Center of Rondônia/BR
/
UNICEF/CH
/
University of São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS